The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia: A Prospective Study
Open accessAbstract
Background —The immunological type of heparin-induced thrombocytopenia (HIT) is the most frequent drug-induced thrombocytopenia. This study evaluated the efficacy of recombinant hirudin (r-hirudin or lepirudin), a potent thrombin inhibitor, for anticoagulation in patients with confirmed HIT. Methods and Results —Eighty-two patients in this prospective, multicenter study received 1 of 4 intravenous r-hirudin regimens: A1, HIT patients with thrombosis (n=51), 0.4-mg/kg bolus and then 0.15 mg · kg −1 · h −1 ; A2, HIT patients with thrombosis receiving thrombolysis (n=5), 0.2-mg/kg bolus and then 0.1 mg · kg −1 · h −1 ; B, HIT patients without thrombosis (n=18), 0.1 mg · kg −1 · h −1 ; and C, during cardiopulmonary bypass surgery (n=8), 0.25-mg/kg bolus and then 5-mg boluses as needed. Response criteria were increase in platelet count by ≥30% to >10 9 /L and activated partial thromboplastin time (aPTT) values 1.5 to 3.0 times baseline values achieved with a maximum of 2 dose increases. No placebo control was used for ethical reasons. Outcomes of a subset of r-hirudin–treated patients who met predefined inclusion criteria (n=71) were compared with those of a historical control group (n=120) for combined and individual incidences of death, amputations, new thromboembolic complications, and incidences of bleeding. Platelet counts increased rapidly in 88.7% of r-hirudin–treated patients with acute HIT. In regimens A1 and A2, the 25% and 75% quartiles of the aPTT were within the target range at all but 1 time point. The incidence of the combined end point (death, amputation, new thromboembolic complications) was significantly reduced in r-hirudin patients compared with historical control patients ( P =0.014). During first selected treatment, the adjusted hazard ratio for r-hirudin patients versus historical control was 0.279 (95% CI, 0.112 to 0.699; P =0.003). Bleeding rates were similar in both groups. Conclusions —r-Hirudin treatment is associated with a rapid and sustained recovery of platelet counts, sufficient aPTT prolongations, and true clinical benefits for patients with HIT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Epidemiologic Research: Principles and Quantitative Methods.
Mayer, L. S., Kleinbaum, D. G., Kupper, L. L., & Morgenstern, H. (1984) · Journal of the American Statistical Association · doi:10.2307/2288427 · Cited by 2,905
Warkentin, T. E., Levine, M. N., Hirsh, J., Horsewood, P., Roberts, R. S., Gent, M., & Kelton, J. G. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322003 · Cited by 2,328
Weitz, J. I., Hudoba, M., Massel, D., Maraganore, J., & Hirsh, J. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114723 · Cited by 1,123
Heparin-induced Thrombocytopenia: Towards Consensus
Warkentin, T. E., Chong, B. H., & Greinacher, A. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614206 · Cited by 542
Self-citationGreinacher, A., Pötzsch, B., Amiral, J., Dummel, V., Eichner, A., & Mueller-Eckhardt, C. (1994) · PubMed · Cited by 492
Self-citationHeparin-induced thrombocytopenia: laboratory studies
Kelton, J., Sheridan, D., Santos, A., Smith, J., Steeves, K., Smith, C., Brown, C., & Murphy, W. (1988) · Blood · doi:10.1182/blood.v72.3.925.925 · Cited by 483
Heparin-Associated Thrombocytopenia
KING, D. J., & KELTON, J. G. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-4-535 · Cited by 480
Warkentin, T., Hayward, C., Boshkov, L., Santos, A., Sheppard, J., Bode, A., & Kelton, J. (1994) · Blood · doi:10.1182/blood.v84.11.3691.bloodjournal84113691 · Cited by 478
Heparin-Induced Thrombocytopenia (HIT): An Overview of 230 Patients Treated with Orgaran (Org 10172)
Magnani, H. N. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649626 · Cited by 435
Cited by
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
“The gene for this protein was then identified, cloned and used recombinantly to provide a new protein therapy, lepirudin, which prevents clot formation in patients with heparin-induced thrombocytopaeni”
MethodAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.64s · Cited by 1,580
Heparin and Low-Molecular-Weight Heparin
Hirsh, J., Warkentin, T. E., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (1998) · Chest · doi:10.1378/chest.114.5_supplement.489s · Cited by 1,031
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Linkins, L.-A., Dans, A. L., Moores, L. K., Bona, R., Davidson, B. L., Schulman, S., & Crowther, M. (2012) · Chest · doi:10.1378/chest.11-2303 · Cited by 1,018
Martel, N., Lee, J., & Wells, P. S. (2005) · Blood · doi:10.1182/blood-2005-04-1546 · Cited by 875
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Warkentin, T. E., Greinacher, A., Koster, A., & Lincoff, A. M. (2008) · Chest · doi:10.1378/chest.08-0677 · Cited by 816
Self-citationHeparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
Warkentin, T. E., & Greinacher, A. (2004) · Chest · doi:10.1378/chest.126.3_suppl.311s · Cited by 809
Self-citationHeparin-Induced Thrombocytopenia
Arepally, G. M., & Ortel, T. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp052967 · Cited by 723
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
Lewis, B. E., Wallis, D. E., Berkowitz, S. D., Matthai, W. H., Fareed, J., Walenga, J. M., Bartholomew, J., Sham, R., Lerner, R. G., Zeigler, Z. R., et al. (2001) · Circulation · doi:10.1161/01.cir.103.14.1838 · Cited by 664
Hirsh, J., Anand, S. S., Halperin, J. L., & Fuster, V. (2001) · Circulation · doi:10.1161/01.cir.103.24.2994 · Cited by 565
Heparin‐induced thrombocytopenia: pathogenesis and management
Warkentin, T. E. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04334.x · Cited by 547
RNA aptamers as reversible antagonists of coagulation factor IXa
Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., & Sullenger, B. A. (2002) · Nature · doi:10.1038/nature00963 · Cited by 512
Goldhaber, S. Z. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16004-2 · Cited by 348
Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo
Szaba, F. M., & Smiley, S. T. (2002) · Blood · doi:10.1182/blood.v99.3.1053 · Cited by 304
Delayed-Onset Heparin-Induced Thrombocytopenia
Rice, L., Attisha, W. K., Drexler, A., & Francis, J. L. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00009 · Cited by 265
Metadata
- Authors
- Greinacher, A., Völpel, H., Janssens, U., Hach-Wunderle, V., Kemkes-Matthes, B., Eichler, P., Mueller-Velten, H. G., & Pötzsch, B.
- Venue
- Circulation
- Published
- 1999-01-12
- Volume
- 99
- Issue
- 1
- Pages
- 73-80
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2109289067
- Cited by
- 482
- References
- 13
- FWCI
- 46.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.